Page 23 - 2020-2021-Heroes-Program-Bklt-v1_fa_Neat

ACS honors Merck for KEYTRUDA, a humanized monoclonal antibody that targets
PD-1 for the treatment of cancer. KEYTRUDA’s aggressive development timeline and

high clinical demand required creativity, strong fundamental science and engineering,
innovative new approaches and understanding of the structure-activity relationship
to enable development of a robust purification and formulation process.

Marc Bastiaansen
With a Ph.D. in Organic Chemistry from the University of Wageningen, The Netherlands, and a
M.S. in Biotechnology, Marc started his career within Organon NV with the commercialization
of Arixtra. For Keytruda, Marc led the cross-functional CMC team. Currently, Marc is leading
cross-functional technical teams for Biologics within Organon.

Parimal Desai
Parimal Desai is currently Vice President in Merck Manufacturing facilitating divisional
transformation strategy execution. Previously, he was head of the Global Vaccines & Biologics
Commercialization responsible to develop and commercialize Merck’s vaccines and biologics
including accelerated launch of Keytruda. Parimal received his Ph.D. in Biochemistry from
Penn State University.

Stephen Farrand
Stephen Farrand is educated in the UK and has 17 years in the UK biotechnology industry.
Stephen relocated to Ireland to assume Manufacturing Director position at Schering-Plough,
and then to Singapore to lead Biotechnology facility. He assumed a VP Biotech Dev role for
Schering-Plough Research Institute in 2004, and subsequently for Merck Research Laboratories.
Stephen is currently a CTO at Jounce Therapeutics.

#HeroesofChemistry 23